We read with interest the article by Reddy et al. 1 regarding central nervous system (CNS) CMV infection in SCT recipients and present two additional patients seen at Memorial Sloan-Kettering Cancer Center, including the imaging and histology findings.
Case 1: A 65-year-old man with diffuse large B-cell lymphoma diagnosed in August 2008 was subsequently found to have concurrent myelodysplastic syndrome and secondary AML. Induction chemotherapy was started with mitoxantrone, etoposide and cytarabine, followed by rituximab and consolidation with idarubicin and cytarabine. In August 2009, the patient received TBI, thiotepa, fludarabine and anti-thymocyte globulin, followed by allogeneic T-cell depleted PBSCT from a matched unrelated donor and additional rituximab.
The post transplant course was complicated by several episodes of CMV reactivation. Serum CMV Ag was positive 3 months after transplant and became negative with valacyclovir. Two months later, his CMV PCR showed 1600 copies, treated again with valacyclovir. At that time, he was diagnosed with chronic GVHD of his colon, duodenum and stomach. Because of pancytopenia, valacyclovir was switched to foscarnet and later switched back to valacyclovir. Serum antigenemia was intermittently positive in January, then negative throughout February of 2010 and again became positive in March of 2010. Serum CMV antigenemia was 6500 copies per mL and acyclovir was started. One week later, the patient was admitted with progressive lethargy, inattentiveness and disorientation. Magnetic resonance imaging showed ependymal contrast enhancement, non-enhancing periventricular white matter lesions and mild hydrocephalus (Figures 1a and b) . Electroencephalogram showed generalized slowing and periods of epileptiform activity. He was unresponsive to acyclovir and the regimen was changed to foscarnet. CSF results showed glucose 74 mg/dL, protein 175 mg/dL, RBC 1/mm 3 , WBC 7/mm 3 , lymphocytes 67%, neutrophils 23% and negative cytology; CSF evaluation for VZV, herpes simplex virus, EBV, fungal and bacterial infection was negative, and CMV PCR was positive. His neurological status and clinical condition rapidly deteriorated. At the family's request, the patient was treated with supportive care only and died 2 weeks later. Post-mortem examination of the brain showed CMV panencephalitis and ventriculitis with intranuclear and intracytoplasmic viral inclusion bodies (Figures 2a and b) .
Case 2: A 6-year-old girl who had received a T-cell depleted related allogeneic PBSCT for ALL presented 6 months after PBSCT with seizures, fever and altered mental status. She had been treated with TBI, thiotepa and CY for recurrent ALL before transplant and antithymocyte globulin, immunoglobulin and corticosteroids post transplant. Clinical course was complicated by prolonged asymptomatic CMV viremia requiring continuous treatment with high-dose ganciclovir (12 mg/kg) and foscarnet (90 mg/kg) for 2 months until serum CMV Ag and culture cleared; however, foscarnet and ganciclovir were continued. One month previously she developed GVHD of the skin, which responded to methylprednisolone and anti-TAC. At the time of her presentation, blood CMV Ag and culture were negative, but CSF showed positive CMV PCR culture and nine WBC, protein 132 mg/dL and glucose 64 mg/dL. Magnetic resonance imaging showed new hydrocephalus and linear enhancement along the ependymal lining of the ventricle (Figure 1c) . She was treated with ganciclovir (15 mg/kg), foscarnet (90 mg/kg) and two doses of cidofovir but had progressive hydrocephalus over the next month. The patient did not improve neurologically and died of sepsis from fungal renal abscess and pneumonia 38 days after diagnosis of CMV encephalitis. No autopsy was performed.
Comment: Similar to the patients reported by Reddy et al., 1 our patients developed severe CMV encephalitis several months after transplant. Both patients had previous systemic CMV viremia and had received previous antiviral therapy, which is a risk factor for the development of CMV encephalitis in conjunction with an immunosuppressed state. Causes of immunosuppression include low CD4 counts and the use of cytotoxic T-cell depleting agents. Our patients had received pre-treatment TBI, chemotherapy and rituximab, all of which potentially added to the immunosuppression. In one report of five patients, three patients with CMV infection post transplant resembled advanced HIV patients with CMV infection with elevated serum viremia, retinitis and extraneural involvement. However, one of the patients did not have elevated viremia or signs of systemic disease. In fact, a second patient was noted to have localization of CMV to the CNS while systemic disease was improving.
2 At the time of his CNS disease, one of our patients had active pulmonary CMV infection, similar but not restricted to the pattern that is seen in advanced HIV patients. Both patients' magnetic resonance imaging showed typical but subtle findings, with ependymal enhancement and non-enhancing periventricular white matter lesions consistent with the 'owl's eye' pattern of CMV ventriculitis. 3 Viral load has been shown to correlate with pathogenicity as in our first patient who had signs of infection when his viral load was elevated. Viral load in transplanted patients is a dynamic process and can double in one day. 4 Use of appropriate antivirals (foscarnet, ganciclovir and cidofovir) did not ameliorate symptoms as both patients continued to deteriorate. This lack of efficacy may reflect the fact that by the time the diagnosis is made and treatment started, the inflammatory process is at advanced stages and widespread in the brain, as observed in viral encephalitis in general. However, it is also possible that viral mutations conferring resistance to antiviral therapy have occurred in the setting of treatment for prolonged CMV viremia. In fact, both groups, patients with advanced HIV and SCT patients appear to have a high frequency of mutations conferring resistance to ganciclovir, such as UL97 and UL 54. Moreover, antivirals have poor blood-brain barrier penetrance and the CNS surveillance against infections is impaired, further providing an environment for CMV latency in the CNS. 5, 6 Although rare, it is important to consider CMV encephalitis in the differential diagnosis of transplanted patients presenting with encephalopathy and implement specific therapy as early as possible.
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